A5100757767- Lung Cancer Treatments and Mutations
- Anesthesia and Neurotoxicity Research
- Lung Cancer Research Studies
- Cancer Cells and Metastasis
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Epigenetics and DNA Methylation
- Cancer-related gene regulation
- Heavy Metal Exposure and Toxicity
- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Neuroendocrine Tumor Research Advances
- Cytokine Signaling Pathways and Interactions
- Cancer therapeutics and mechanisms
- Neurological Disease Mechanisms and Treatments
- Kruppel-like factors research
- Gastrointestinal Tumor Research and Treatment
- Biochemical effects in animals
- Neonatal and fetal brain pathology
- Environmental and Agricultural Sciences
- Hydrology and Watershed Management Studies
- Histone Deacetylase Inhibitors Research
Qilu Hospital of Shandong University
2013-2025
Jinan University
2024
China National Salt Industry Corporation (China)
2024
Chinese Academy of Sciences
2009-2024
Huawei Technologies (China)
2023-2024
Jilin University
2022
State Key Laboratory of Superhard Materials
2022
Shandong University
2009-2022
Zero to Three
2022
Second Xiangya Hospital of Central South University
2021
Abstract Despite neoadjuvant/conversion chemotherapy, the prognosis of cT4a/bN+ gastric cancer is poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in late-stage cancer, but their efficacy setting unclear. In this single-armed, phase II, exploratory trial (NCT03878472), we evaluate a combination ICI (camrelizumab), antiangiogenesis (apatinib), chemotherapy (S-1 ± oxaliplatin) for treatment cancer. The primary endpoints are pathological responses...
Background SMARCA4, the essential ATPase subunit of SWI/SNF chromatin remodeling complex, regulates transcription through control structure and is increasingly thought to play significant roles in human cancers. This study aims explore potential role SMARCA4 with a view providing insights on pathologic mechanisms implicated here. Methods The different tumors were explored based Cancer Genome Atlas (TCGA), Genotype-tissue expression (GTEx), Tumor Immune Estimation Resource (TIMER), Gene Set...
Closely located at the tumor suppressor locus 16q22.1, CKLF-like MARVEL transmembrane domain-containing member 3 and 4 (CMTM3 CMTM4) encode two CMTM family proteins, which link chemokines transmembrane-4 superfamily. In contrast to broad expression of both CMTM3 CMTM4 in normal human adult tissues, only is silenced or down-regulated common carcinoma (gastric, breast, nasopharyngeal, esophageal, colon) cell lines primary tumors. methylation was not detected epithelial with weak present 5 35...
A disintegrins and metalloproteinases with thrombospondin motifs (ADAMTS) family members have been reported dysregulated in various cancers. Through refining a loss of heterozygosity locus at 11q25 by array-CGH, we identified ADAMTS8 as novel candidate tumor suppressor gene. Although downregulation has several tumors, its biologic function underlying mechanism remain largely unknown. Here, found that is broadly expressed normal tissues but frequently downregulated or silenced promoter...
Cancer progression requires a permissive microenvironment that shields cancer from the host immunosurveillance. The presence of myeloid-derived suppressor cells (MDSC) is key feature tumor-permissive microenvironment. Cullin 4B (CUL4B), scaffold protein in 4B-RING E3 ligase complex (CRL4B), represses tumor suppressors through diverse epigenetic mechanisms and overexpressed many malignancies. We report here CUL4B unexpectedly functions as negative regulator MDSC multiple settings. Conditional...
Despite limited efficacy of immunotherapy for advanced non-small-cell lung cancer (NSCLC) with driver mutations, whether neoadjuvant could be clinically valuable in those patients warrants further investigation. We utilized 40 oncogene-mutant NSCLC treated induction from a large consecutive multicenter cohort. Overall response rate was 62.5% while 2 had disease progression. Of 39 that received surgery, R0 resection 97.4%. The major pathological (MPR) 37.5% and the complete (pCR) 12.5%....
Abstract Immune checkpoint inhibitor (ICI) rechallenge in non‐small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI can be divided into three categories: adverse events (AEs); resistance to ICIs, and becomes compulsive because of tumor relapse while the patients had completed 2 year course immunotherapy. However, these categories are still controversial should explored further. Through voting at 6th Straits Summit Forum on Lung Cancer, this study we...
As one of the most aggressive human malignancies, pancreatic cancer is a leading cause cancer-related deaths worldwide and only about 4 % patients will live 5 years after diagnosis. Eighty to approximately eighty-five percent are diagnosed with an unresectable or metastatic disease, which correlated poor prognosis low survival rate. Therefore, it tremendously significant exploit novel chemicals prevent treat cancer. Previous research clinical studies have demonstrated that many natural...
Class III β-tubulin, Sox2, and Survivin play important roles in tumor survival proliferation. However, the association of these three factors with clinicopathological characteristics, chemoresistance, patients ovarian cancer remains controversial.We investigated predictive value correlation among expression levels 110 stage epithelial cancer, including 58 who received taxane-based chemotherapy 52 non-taxane-based chemotherapy. Expression was immunohistochemically examined tissues obtained...
Microsatellite stable (MSS) or mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) is resistant to immune checkpoint inhibitors. However, a recent Japanese trial showed that regorafenib plus nivolumab had encouraging anti-cancer activity in MSS pMMR mCRCs.We retrospectively reviewed the efficacy and safety data of combination therapy with anti-PD-1 antibody patients refractory mCRC medical centers Shandong Province China.Twenty-three received antibody. Eighteen (78.3%)...
(1) Background: At present, the efficacy and safety of thoracic radiotherapy (TRT) after chemo-immunotherapy (CT-IT) in patients with extensive-stage small-cell lung cancer (ES-SCLC) still remain unclear. The purpose this study was to evaluate role TRT CT-IT ES-SCLC. (2) Methods: From January 2020 October 2021, ES-SCLC treated first-line anti-PD-L1 antibody plus platinum-etoposide chemotherapy were enrolled retrospectively. survival data adverse events or without collected for analysis. (3)...
Abstract Background Patients with extensive‐stage small cell lung cancer (ES‐SCLC) have an exceptionally poor prognosis and immune checkpoint inhibitors (ICIs) combined etoposide‐platinum is recommended as standard first‐line therapy. However, which combination pattern the best still remains unknown. This network meta‐analysis was performed to compare efficacy safety of currently available patterns including antiangiogenic agent containing regimen probed into most appropriate therapy for...
Alterations in the mesenchymal-epithelial transition factor (MET) gene are critical drivers of non-small cell lung cancer (NSCLC). In recent years advances precision therapies targeting MET alterations have significantly expanded treatment options for NSCLC patients. These include exon 14 skipping mutations (MET skipping), amplifications, point (primarily kinase domain mutations), and protein overexpression. Accurate identification these appropriate selection patient populations targeted...
The rearranged during transfection (RET) gene is one of the receptor tyrosine kinases and cell-surface molecules responsible for transmitting signals that regulate cell growth differentiation. In non-small lung cancer (NSCLC), RET fusion a rare driver alteration associated with poor prognosis. Fortunately, two selective inhibitors (sRETi), namely pralsetinib selpercatinib, have been approved treating NSCLC due to their remarkable efficacy safety profiles. These shown ability overcome...
Abstract The fusion genes NRG1 and NRG2, members of the epidermal growth factor (EGF) receptor family, have emerged as key drivers in cancer. Upon fusion, retains its EGF-like active domain, binds to ERBB ligand triggers intracellular signaling cascades, promoting uncontrolled cell proliferation. incidence gene varies across cancer types, with lung being most prevalent at 0.19 0.27%. CD74 SLC3A2 are frequently observed partners. RNA-based next-generation sequencing is primary method for...
Esophageal squamous cell carcinoma (ESCC) is highly prevalent in China and other Asian countries, as a major cause of cancer-related mortality. ESCC displays complex chromosomal abnormalities, including multiple structural numerical aberrations. Chromosomal such recurrent amplifications homozygous deletions, directly contribute to tumorigenesis through altering the expression key oncogenes tumor suppressor genes. To understand role genetic alterations pathogenesis identify critical...
Abstract Epilepsy is a multi-etiological brain dysfunction syndrome. Hippocampal neuronal damage induced by seizures may be one of the causes leading to cognitive impairment, but underlying mechanism remains further elucidated. The kainic acid (KA) model temporal lobe epilepsy widely used in understanding epileptogenesis. Fiber photometry signal detection technology suitable for recording calcium activity neurons deep freely moving animal. Here, we optical fiber-based method monitor...
Abstract Background Mutation in SPINK5 causes Netherton syndrome, a rare recessive skin disease that is accompanied by severe atopic manifestations including dermatitis, allergic rhinitis, asthma, high serum IgE and hypereosinophilia. Recently, single nucleotide polymorphism (SNP) of the was shown to be significantly associated with atopy, total IgE. In order determine role development case-control study 669 asthma patients 711 healthy controls Han Chinese conducted. Methods Using PCR-RFLP...
Recent studies suggest that paired box 5 (PAX5) is down-regulated in multiple tumours through its promoter methylation. However, the role of PAX5 non-small cell lung cancer (NSCLC) pathogenesis remains unclear. The aim this study to examine expression, methylation status, biological functions and related molecular mechanism NSCLC. We found was widely expressed normal adult tissues but silenced or 88% (7/8) NSCLC lines. expression level significantly lower than adjacent non-cancerous (P =...
Regorafenib improves progression-free survival (PFS) and overall (OS) in patients with refractory metastatic colorectal cancer (mCRC). Here, we report the treatment patterns of regorafenib third- or late-line setting for mCRC four centers China.Patients China administered from February 1, 2018 to June 31, 2021 were enrolled. Patients grouped into 3 cohorts, namely, monotherapy (regorafenib alone), chemo plus chemotherapy), immune [regorafenib anti-PD1 (programmed cell death 1) antibodies]...
Abstract Background For patients with advanced non‐small cell lung cancer (NSCLC) who have received frontline immunochemotherapy, subsequent treatment options are limited. As the first dual programmed death‐1 (PD‐1)/cytotoxic T lymphocyte‐associated antigen‐4 bispecific antibody approved globally, cadonilimab demonstrated potential antitumor activity in NSCLC resistant to anti‐PD‐1/PD‐L1 antibodies. Methods We retrospectively collected efficacy and safety data from treated cadonilimab‐based...